Real-world evidence for frequency of constipation with the use of anti-CGRP monoclonal antibodies in chronic migraine

被引：0
|
作者：
Uzun, S. [1 ,2 ]
Frejvall, U. [1 ]
Sahin, G. Ozkaya [3 ,4 ]
Sahin, G. [1 ,2 ]
机构：
[1] Skaneuro Neurol Clin, Lund, Sweden
[2] Lund Univ, Dept Clin Sci Malmo & Lund, Lund, Sweden
[3] Lund Univ, Dept Lab Med, Lund, Sweden
[4] Lund Univ, Dept Translat Med, Lund, Sweden
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P015
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Long-term effectiveness of monoclonal anti-CGRP antibodies in patients with migraine in real life
    Perez Prol, C.
    Espinoza Vinces, C.
    Villino Rodriguez, R.
    Atorrasagasti Villar, A.
    Gimeno Rodriguez, M.
    Benitez Martinez, B.
    Beistegui Sarobe, M.
    Sanchez del Rio, M.
    Irimia Sieira, P.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [42] Efficacy and Safety of Anti-CGRP Monoclonal Antibodies for Migraine Preventative Treatment
    Salim, Amira
    Najjar, Atia
    Ahmed, Zubair
    Mata, Ignacio
    NEUROLOGY, 2023, 100 (17)
  • [43] ANTI-CGRP MONOCLONAL ANTIBODIES FOR NEUROPATHIC PAIN IN PATIENTS WITH MIGRAINE HEADACHE
    Kang, Seung Ah
    Govindarajan, Raghav
    MUSCLE & NERVE, 2020, 62 : S7 - S7
  • [44] Anti-CGRP Monoclonal Antibodies for Neuropathic Pain in Patients with Migraine Headache
    Kang, Seung Ah
    Govindarajan, Raghav
    NEUROLOGY, 2021, 96 (15)
  • [45] Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA. The RAMO study: early results
    Montisano, D. A.
    Giossi, R.
    Canella, M.
    Vernieri, F.
    Altamura, C.
    Grazzi, L.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [46] Real-world effectiveness of Anti-CGRP Monoclonal antibodies compared to OnabotulinumtoxinA. The RAMO study: early results
    Montisano, Danilo Antonio
    Giossi, Riccardo
    Canella, Mattia
    Altamura, Claudia
    Vernieri, Fabrizio
    Ferrarese, Carlo
    Grazzi, Licia
    CEPHALALGIA, 2023, 43 (1supp) : 228 - 229
  • [47] Predictors of response to anti-CGRP monoclonal antibodies: a scoping review and meta-analysis of real-world experience
    Hong, J. B.
    Lange, K. S.
    Overeem, L. H.
    Triller, P.
    Raffaelli, B.
    Reuter, U.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [48] Switching OnabotulinumtoxinA and Monoclonal Antibodies Anti-CGRP in Severe, Drugs-Resistant Chronic Migraine
    Iannone, L. F.
    Chiarugi, A.
    Fattori, D.
    De Cesaris, F.
    Geppetti, P.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [49] When chronic migraine remains refractory: can anti-CGRP monoclonal antibodies be combined with onabotulinumtoxinA?
    Martins Silva, E.
    Pereira, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 611 - 611
  • [50] OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
    Argyriou, Andreas A. A.
    Dermitzakis, Emmanouil V. V.
    Xiromerisiou, Georgia
    Vikelis, Michail
    TOXINS, 2022, 14 (12)
12345